Predict S.p.A. Advances Growth with Share Conversion and Stock Grant Plan

Predict S.P.A. Class B ( (IT:PRE) ) has issued an announcement.

Predict S.p.A.’s Board of Directors has approved the conversion of 150,000 Price Adjustment Shares into ordinary shares and the allocation of 300,000 shares under the Stock Grant Plan 2025, following the achievement of the 2024 EBITDA targets. This move, which increases the company’s share capital, aims to support Predict’s growth by incentivizing key employees, potentially strengthening its market position in the innovative healthcare sector.

The most recent analyst rating on (IT:PRE) stock is a Buy with a EUR1.45 price target. To see the full list of analyst forecasts on Predict S.P.A. Class B stock, see the IT:PRE Stock Forecast page.

More about Predict S.P.A. Class B

Predict S.p.A., established in 2008 in Bari, is an innovative SME in the healthcare sector, focusing on in vivo diagnostics, breath analysis, and digital healthcare technologies. The company operates through four Strategic Business Units, offering solutions in diagnostic imaging, breath analysis, and augmented reality and robotics for healthcare professionals. Predict has developed technologies like Mistral for non-invasive disease screening and Aphel for robotic support, and maintains partnerships with leading Italian research institutes.

Average Trading Volume: 41,054

Technical Sentiment Signal: Strong Buy

For a thorough assessment of PRE stock, go to TipRanks’ Stock Analysis page.